IONIS ANGPTL3LRx

Drug Profile

IONIS ANGPTL3LRx

Alternative Names: AKCEA-ANGPTL3-LRX; IONIS-ANGPTL3-LRX

Latest Information Update: 09 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Akcea Therapeutics; Ionis Pharmaceuticals
  • Class Antihyperlipidaemics; Antisense oligonucleotides
  • Mechanism of Action ANGPTL3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hyperlipoproteinaemia type IIa

Most Recent Events

  • 08 Aug 2017 Akcea plans a phase II trial for Non-alcoholic fatty liver disease and Hyperlipidemias in the second half of 2017
  • 25 May 2017 Updated efficacy and adverse events data from a phase I/II trial in Liver disorders released by Akcea Therapeutics
  • 01 Mar 2017 Ionis Pharmaceuticals plans a clinical trial for Liver disorders (non-alcoholic fatty liver disease or non-alcoholic steatohepatitis) (Ionis Pharmaceuticals 10-K, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top